Parvovirus B19 acute infection and a reactivation of cytomegalovirus and herpesvirus 6 in a chronic myeloid leukemia patient during treatment with dasatinib (BMS-354825).
García-Muñoz
Ricardo
R
Galar
Alicia
A
Moreno
Cristina
C
Rodríguez-Otero
Paula
P
Panizo-Morgado
Elena
E
Ponz-Sarvisê
Mariano
M
Fernandez-Alonso
Mirian
M
Rubio
Manuel
M
Merino
Juana
J
Cuesta
Braulia
B
Panizol
Carlos
C
Prosper
Felipe
F
D000208:Acute Disease; D003587:Cytomegalovirus / Q000502:physiology*; D000069439:Dasatinib; D005260:Female; D015654:Herpesvirus 6, Human / Q000502:physiology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000209:etiology*; D016732:Parvovirus B19, Human; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D013844:Thiazoles / Q000009:adverse effects*; D014775:Virus Activation / Q000187:drug effects*
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib